NSC 405020
Based on 3 publication(s) in Google Scholar
NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 405020 reduces the expression of full length and active cleaved Notch3 (NICD3). NSC 405020 can be used to research vestibular schwannoma, hemostasis and thrombosis.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 7497-07-6
- Formula: C12H15Cl2NO
- Molecular Weight:260.16
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) NSC 405020
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biological Activity
MMP14[1]
NSC 405020 (100 and 1000 μM; 0-30 min) inhibits MMP-14 levels by over 85% with a dose-dependent manner in the plasma sample from vestibular schwannoma group[1].
?
NSC 405020 (50 μM) reduces expression of the full length and active cleaved Notch3 (NICD3) by 42% in the WM852 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 7497-07-6
-
Appearance Solid
-
Molecular Weight 260.16
-
Formula C12H15Cl2NO
-
Color White to off-white
-
SMILES
O=C(NC(C)CCC)C1=CC=C(Cl)C(Cl)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Exp Hematol Oncol
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway. [Abstract]2025 Mar 22;14(1):43. PMID: 40121502
NSC 405020 purchased from MedChemExpress. Usage Cited in: Exp Hematol Oncol. 2025 Mar 22;14(1):43. [Abstract]
A-D. AML cell lines, Kasumi-1 and Molm-13, were co-cultured with MSCs and treated for 48 hours with the inhibitor (NSC 405020; 10, 20 μM), Ara-C (0.5, 1 μM), or their combination. Apoptosis rates were measured by flow cytometry, andthe combination index (CI) was calculated using CompuSyn software, revealing synergistic effects (CI < 1) between the inhibitor and Ara-C.
NSC 405020 purchased from MedChemExpress. Usage Cited in: Exp Hematol Oncol. 2025 Mar 22;14(1):43. [Abstract]
AML cell lines, Kasumi-1 and Molm-13, were co-cultured with MSCs and treated for 48 hours with the inhibitor (NSC 405020; 20 μM), Ara-C (1 μM), or their combination. Western blot analysis of STAT3, P-STAT3, STAT5, and P-STAT5 protein expression in Kasumi-1 and Molm-13 cells co-cultured with MSCs.
NSC 405020 purchased from MedChemExpress. Usage Cited in: Exp Hematol Oncol. 2025 Mar 22;14(1):43. [Abstract]
MMP14 inhibitor (NSC 405020) combined with cytarabine group showed highest survival rate and the proportion of bone marrow and splenic leukemia cells in mice treated with the combination of MMP14 inhibitor and cytarabine was significantly lower than in the control and single-agent groups.
-
Cell Rep
AMPK Activation Regulates LTBP4-Dependent TGF-β1 Secretion by Pro-inflammatory Macrophages and Controls Fibrosis in Duchenne Muscular Dystrophy. [Abstract]2018 Nov 20;25(8):2163-2176. PMID: 30463013
NSC 405020 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2018 Nov 20;25(8):2163-2176. [Abstract]
NSC-405020 (10 mg/kg; ip; every 3 days during the 2 weeks) in fib-mdx mice showed a significant improvement in the muscle, including reduction in necrosis (60%), reduction in fibrosis (11%).
NSC 405020 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2018 Nov 20;25(8):2163-2176. [Abstract]
NSC-405020 (10 mg/kg; ip; every 3 days during the 2 weeks) in fib-mdx mice showed a myofiber CSA distribution shift to larger myofibers.
-
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576
Solvent & Solubility
DMSO : ≥ 260 mg/mL (999.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ren Y, et al. MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas. Front Cell Neurosci. 2020 Jul 28;14:191. [Content Brief]
[2]. Pekkonen P, et al. Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation. Elife. 2018 May 1;7:e32490. [Content Brief]
[3]. Mastenbroek TG, et al. Platelet-Associated Matrix Metalloproteinases Regulate Thrombus Formation and Exert Local Collagenolytic Activity. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2554-61. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8438 mL | 19.2189 mL | 38.4379 mL | 96.0947 mL |
| 5 mM | 0.7688 mL | 3.8438 mL | 7.6876 mL | 19.2189 mL | |
| 10 mM | 0.3844 mL | 1.9219 mL | 3.8438 mL | 9.6095 mL | |
| 15 mM | 0.2563 mL | 1.2813 mL | 2.5625 mL | 6.4063 mL | |
| 20 mM | 0.1922 mL | 0.9609 mL | 1.9219 mL | 4.8047 mL | |
| 25 mM | 0.1538 mL | 0.7688 mL | 1.5375 mL | 3.8438 mL | |
| 30 mM | 0.1281 mL | 0.6406 mL | 1.2813 mL | 3.2032 mL | |
| 40 mM | 0.0961 mL | 0.4805 mL | 0.9609 mL | 2.4024 mL | |
| 50 mM | 0.0769 mL | 0.3844 mL | 0.7688 mL | 1.9219 mL | |
| 60 mM | 0.0641 mL | 0.3203 mL | 0.6406 mL | 1.6016 mL | |
| 80 mM | 0.0480 mL | 0.2402 mL | 0.4805 mL | 1.2012 mL | |
| 100 mM | 0.0384 mL | 0.1922 mL | 0.3844 mL | 0.9609 mL |
Powered by Bioz